中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

乙型肝炎肝硬化患者伴或不伴腹水对肠道菌群的影响

栾雨婷 蔡文君 蒋轼丽 赵长青 顾宏图 袁继丽 邢枫 吕靖 刘成海 刘平 慕永平

栾雨婷, 蔡文君, 蒋轼丽, 赵长青, 顾宏图, 袁继丽, 邢枫, 吕靖, 刘成海, 刘平, 慕永平. 乙型肝炎肝硬化患者伴或不伴腹水对肠道菌群的影响[J]. 临床肝胆病杂志, 2020, 36(7): 1520-1526. DOI: 10.3969/j.issn.1001-5256.2020.07.015.
引用本文: 栾雨婷, 蔡文君, 蒋轼丽, 赵长青, 顾宏图, 袁继丽, 邢枫, 吕靖, 刘成海, 刘平, 慕永平. 乙型肝炎肝硬化患者伴或不伴腹水对肠道菌群的影响[J]. 临床肝胆病杂志, 2020, 36(7): 1520-1526. DOI: 10.3969/j.issn.1001-5256.2020.07.015.
Luan YuTing, Cai WenJun, Jiang ShiLi, Zhao ZhangQing, Gu HongTu, Yuan JiLi, Xing Feng, Lu: Jing, Liu ChengHai, Liu Ping, Mu YongPing. A comparative study of intestinal flora between hepatitis B cirrhosis patients with or without ascites[J]. J Clin Hepatol, 2020, 36(7): 1520-1526. DOI: 10.3969/j.issn.1001-5256.2020.07.015.
Citation: Luan YuTing, Cai WenJun, Jiang ShiLi, Zhao ZhangQing, Gu HongTu, Yuan JiLi, Xing Feng, Lu: Jing, Liu ChengHai, Liu Ping, Mu YongPing. A comparative study of intestinal flora between hepatitis B cirrhosis patients with or without ascites[J]. J Clin Hepatol, 2020, 36(7): 1520-1526. DOI: 10.3969/j.issn.1001-5256.2020.07.015.

乙型肝炎肝硬化患者伴或不伴腹水对肠道菌群的影响

DOI: 10.3969/j.issn.1001-5256.2020.07.015
基金项目: 

国家自然科学基金面上项目资助(81573948; 81874390); 

详细信息
  • 中图分类号: R512.62;R575.2

A comparative study of intestinal flora between hepatitis B cirrhosis patients with or without ascites

Research funding: 

 

  • 摘要: 目的探讨乙型肝炎肝硬化(HBLC)伴有或不伴有腹水患者肠道菌群的差异。方法收集2016年10月-12月于上海中医药大学附属曙光医院肝硬化科就诊的HBLC患者57例,其中无腹水30例(HBLC-WOA),有腹水但无SBP 27例(HBLCWA),并纳入28例健康志愿者(HC),采用16S rRNA测序技术,比较两组肝硬化患者间肠道菌群的分布差异。计数资料2组间比较采用Wilcoxon秩和检验;计量资料2组间比较采用Mann-Whitney U检验,3组比较采用Kruskal-Wallis H检验。组间各物种相对丰度差异的比较采用多重假设检验,采用Benjamini和Hochberg错误发现率(fdr)进行调整,Pfdr<0. 05为差异有统计学意义。相关分析采用Spearman秩相关检验。不同条件下组间的差异比较采用相似性分析(ANOSIM)和非参数多元方差分析(Adonis)。结果伴随腹水的出现,HBLC患者粪便微生物群的多样性降低(P=0. 042)。PCo A结果显示,HBLC-WOA组、HBLC-WA组与HC组间比较差异有统计学意义(HBLC-WOA vs HC,ANOSI...

     

  • [1]LU FM,ZHUANG H.Management of hepatitis B in China[J].Chin Med J(Engl),2009,122(1):3-4.
    [2]WANG FS,FAN JG,ZHANG Z,et al.The global burden of liver disease:The major impact of China[J].Hepatology,2014,60(6):2099-2108.
    [3]HENDRIKX T,SCHNABL B.Antimicrobial proteins:Intestinal guards to protect against liver disease[J].J Gastroenterol,2019,54(3):209-217.
    [4]SENDER R,FUCHS S,MILO R.Revised estimates for the number of human and bacteria cells in the body[J].PLo S Biol,2016,14(8):e1002533.
    [5]HARTMANN P,CHEN WC,SCHNABL B.The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease[J].Front Physiol,2012,3:402.
    [6]LIN R,ZHOU L,ZHANG J,et al.Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis[J].Int J Clin Exp Pathol,2015,8(5):5153-5160.
    [7]BHAT M,ARENDT BM,BHAT V,et al.Implication of the intestinal microbiome in complications of cirrhosis[J].World J Hepatol,2016,8(27):1128-1136.
    [8]GINS P,QUINTERO E,ARROYO V,et al.Compensated cirrhosis:Natural history and prognostic factors[J].Hepatology,1987,7(1):122-128.
    [9]D'AMICO G,GARCIA-TSAO G,PAGLIARO L.Natural history and prognostic indicators of survival in cirrhosis:A systematic review of 118studies[J].J Hepatol,2006,44(1):217-231.
    [10]van ERPECUM KJ.Ascites and spontaneous bacterial peritonitis in patients with liver cirrhosis[J].Scand J Gastroenterol Suppl,2006,243:79-84.
    [11]GINS P,CRDENAS A,ARROYO V,et al.Management of cirrhosis and ascites[J].N Engl J Med,2004,350(16):1646-1654.
    [12]BENTEN D,WIEST R.Gut microbiome and intestinal barrier failure-the“Achilles heel”in hepatology?[J].J Hepatol,2012,56(6):1221-1223.
    [13]WIEST R,KRAG A,GERBES A.Spontaneous bacterial peritonitis:Recent guidelines and beyond[J].Gut,2012,61(2):297-310.
    [14]WIEST R,GARCIA-TSAO G.Bacterial translocation(BT)in cirrhosis[J].Hepatology,2005,41(3):422-433.
    [15]NOLAN JP.The role of intestinal endotoxin in liver injury:A long and evolving history[J].Hepatology,2010,52(5):1829-1835.
    [16]GILL SR,POP M,DEBOY RT,et al.Metagenomic analysis of the human distal gut microbiome[J].Science,2006,312(5778):1355-1359.
    [17]CHEN Y,YANG F,LU H,et al.Characterization of fecal microbial communities in patients with liver cirrhosis[J].Hepatology,2011,54(2):562-572.
    [18]SANTIAGO A,POZUELO M,POCA M,et al.Alteration of the serum microbiome composition in cirrhotic patients with ascites[J].Sci Rep,2016,6:25001.
    [19]KANG Y,CAI Y.Gut microbiota and hepatitis-B-virus-induced chronic liver disease:Implications for faecal microbiota transplantation therapy[J].J Hosp Infect,2017,96(4):342-348.
    [20] QIN J,LI R,RAES J,et al.A human gut microbial gene catalogue established by metagenomic sequencing[J].Nature,2010,464(7285):59-65.
    [21]LU H,WU Z,XU W,et al.Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection.Intestinal microbiota of HBV cirrhotic patients[J].Microb Ecol,2011,61(3):693-703.
    [22]TUOMISTO S,PESSI T,COLLIN P,et al.Changes in gut bacterial populations and their translocation into liver and ascites in alcoholic liver cirrhotics[J].BMC Gastroenterol,2014,14:40.
    [23]BAJAJ JS,BETRAPALLY NS,HYLEMON PB,et al.Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy[J].Hepatology,2015,62(4):1260-1271.
    [24]QIN N,YANG F,LI A,et al.Alterations of the human gut microbiome in liver cirrhosis[J].Nature,2014,513(7516):59-64.
    [25]WEI X,YAN X,ZOU D,et al.Abnormal fecal microbiota community and functions in patients with hepatitis B liver cirrhosis as revealed by a metagenomic approach[J].BMC Gastroenterol,2013,13:175.
    [26]FAITH JJ,GURUGE JL,CHARBONNEAU M,et al.The longterm stability of the human gut microbiota[J].Science,2013,341(6141):1237439.
    [27]BAJAJ JS,HEUMAN DM,HYLEMON PB,et al.Altered profile of human gut microbiome is associated with cirrhosis and its complications[J].J Hepatol,2014,60(5):940-947.
    [28]BALMER ML,SLACK E,de GOTTARDI A,et al.The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota[J].Sci Transl Med,2014,6(237):237ra66.
    [29]PONZIANI FR,ZOCCO MA,CERRITO L,et al.Bacterial translocation in patients with liver cirrhosis:Physiology,clinical consequences,and practical implications[J].Expert Rev Gastroenterol Hepatol,2018,12(7):641-656.
    [30]TANG R,WEI Y,LI Y,et al.Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J].Gut,2018,67(3):534-541.
    [31]YANG R,XU Y,DAI Z,et al.The immunologic role of gut microbiota in patients with chronic HBV infection[J].J Immunol Res,2018,2018:2361963.
    [32]TILG H,CANI PD,MAYER EA.Gut microbiome and liver diseases[J].Gut,2016,65(12):2035-2044.
  • 加载中
计量
  • 文章访问数:  1358
  • HTML全文浏览量:  16
  • PDF下载量:  160
  • 被引次数: 0
出版历程
  • 出版日期:  2020-07-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回